At FimmCyte our vision is to develop a cure for endometriosis. Every tenth woman has endometriosis, but besides pain management and surgery there are no alternatives. At FimmCyte we have developed a novel therapy which has proven to be highly effective in animal and ex-vivo models. This is the first immune based therapy for endometriosis and once successful will provide patients and healthcare providers a much-needed tool to fight this painful disease.
Our objective over the next 12-18 months is to fine-tune our endometriosis treatment so that it is applicable to as many women with endometriosis as possible. This work will be carried out by FimmCyte AG and the University of Zurich/University Hospital Zurich. After reaching a frozen design FimmCyte will seek to conduct first in-human studies.
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 02.06.2022